Dasatinib

Catalog No.S1021 Synonyms: BMS-354825

Dasatinib Chemical Structure

Molecular Weight(MW): 488.01

Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.

Size Price Stock Quantity  
In DMSO USD 140 In stock
USD 147 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 66 Publications

13 Customer Reviews

  • Antitumor activity (A)and body weight (B) relationship for BLU-285 and dasatinib in a P815 KIT D814Y mastocytoma allograft model.

    Science, 2017, 9(414), doi: 10.1126/scitranslmed.aao1690. Dasatinib purchased from Selleck.

    Combinational treatment of kinase inhibitors induces the similar phenotype produced by PP1. All images are lateral view with dorsal to the top and anterior to the left. The combinational treatment of Dasatinib (D) or U0126 (U) with Sunitinib (SU),PTK787 (PTK), or ZM323881 (Z) resulted in the shrinkage of dorsal aorta.

    Cell Res 2011 21, 1080-1087. Dasatinib purchased from Selleck.

  • Cytotoxicity by Dasatinib and Nutlin-3 used alone or in combination in B-CLL patient leukemic cells. B-CLL patient leukemic cells were exposed to serial doses of Dasatinib or Nutlin- 3 used either alone or in combination, with a fixed ratio, for 48 hours. Dose-effect plots, to determine drug efficacy, are shown for representative B-CLL samples, including 3 patients carrying 17p- (Pt. #7, Pt. #8, and Pt. #10). The decrease of cell viability, labeled "effect" on the Y-axis, was determined in assays done at least twice in duplicate.

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

    Dasatinib interferes with the p53 transcriptional activity induced by Nutlin-3. Leukemic cell lines were exposed for 24 hours to Dasatinib (10 μM) and Nutlin-3 (10 μM), used either alone or in combination, as indicated. Levels of p53 (A), MDM2 and p21 (B) were assessed by Western blot analysis of total cell lysates. Representative examples of Western blot results are shown. Tubulin staining is shown as loading control; after densitometric analyses, p53 as well as MDM2 and p21 protein levels are expressed as folds of protein modulation, by the indicated treatments, with respect to the control untreated cultures set to 1 (hatched line). *P < 0.05 with respect to the Nutlin-3-treated cultures.

     

     

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

  • Role of Akt in Dasatinib cytotoxicity and in DasatinibtNutlin-3 synergy. A, whole cell lysates were prepared from EHEB and BJAB cell lines treated (for 16 hours) as indicated, and hybridized with a human Phospho-Kinase array kit. Spot densities of phospho-proteins were quantified using Image Quant TL software and normalized to those of positive controls (set at 100) on the same membrane. The analysis of modulation of phosphorylation signals for P-ERK1/2, P-p38, and P-Akt are reported (*P < 0.05). Validation of phospho-kinase array results was carried out by Western blot analysis of P-Akt levels.

     

     

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

    Impact of the TKI erlotinib, lapatinib, dasatinib, and sorafenib on the viability of MDS/AML cells. MOLM-13 (A) and HL-60 (B) cells were incubated with the indicated doses (given in mM below the x-axis) of the 4 TKI, and cellular viability was assessed by MTT assay after 24, 48 and 72 h of incubation. Changes in viability are given as percentage of cells as compared to non-treated control samples. This experiment was repeated at least three times, yielding comparable results. Graphs show representative results of one experiment carried out in duplicates (mean standard deviation).

     

     

    Biochem Pharmacol 2011 82, 1457-1466. Dasatinib purchased from Selleck.

  • Capacity of the TKI to overcome the AML-typical differentiation blockage. The myeloid cell lines MOLM-13 and HL-60 were incubated for 6 days with 0.01% DMSO (serving as a negative solvent control), 1 μM of ATRA (serving as a positive control), as well as with the indicated doses of the four TKI. (A) Representative May -Gruenwald -Giemsa staining of MOLM-13 cells, (B) quantitation of the percentage of MOLM-13 cells exhibiting at least two morphological signs of differentiation (that is a decrease in cytoplasmic basophilia, a reduction of the nucleo-cytoplasmic ratio, appearance of nuclear lobulation and/or cytoplasmic granules). Percentages were evaluated by examining at least 100 cells/condition; (C) representative FACS overlays of MOLM-13 cells depicting TKI-induced CD11b expression (black line) as compared to the isotype (shaded grey); (D) quantitation of TKI-induced CD11b-expression in MOLM-13 cells; (E) representative slides depicting morphology/staining of MOLM-13 cells assessed in the NBT-reduction assay; (F) respective quantitative assessment demonstrating the NBT-reducing capacity under the different drugs; (G) representative May-Gruenwald-Giemsa staining of HL-60 cells.

     

     

    Biochem Pharmacol 2011 82, 1457-1466. Dasatinib purchased from Selleck.

    Cytotoxicity by Dasatinib treatment in leukemic cells.Leukemic cell lines were exposed to Dasatinib (10 μM). Upon treatment, cell viability (a) was calculated as percentage with respect to the control vehicle cultures (set to 100% for each cell line) and induction of apoptosis (b) was calculated as percentage of Annexin V+/PI+ cells after 48 h of treatment.

     

     

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

  • Human phospho-kinase array analysis in response to Dasatinib treatment. Whole cell lysates were prepared from EHEB (p53wt) and BJAB (p53mut) B cell lines, either left untreated or exposed to Dasatinib for 24 h, and hybridized with a human Phospho-Kinase array kit. Spot densities of phospho-proteins were quantified using Image Quant TL software and normalized to those of positive controls on the same membrane. In a, intense decreases of signal of P-p38, PERK1/2 and P-CREB in response to Dasatinib are indicated by arrows in the membranes, and intensity of corresponding spots are reported as graphics. In b, analysis of modulation of phosphorylation of STAT family members in response to Dasatinib (spots not shown). The means±SD of three independent experiments are shown. Asterisk indicates P<0.05 against untreated.

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

    Cells were either left untreated (Unt.) or exposed to Dasatinib (Das.) for 24 h. Equal amounts of cell lysates were analyzed for ERK1/2, p38 and CREB phosphorylation by Western blot using antibodies specific for the native form of the kinases and for residues that are phosphorylated (P-) in each kinase upon activation. One of three experimentswith similar results is shown. Protein bands were quantified by densitometry and level of PERK1/2, P-p38 and P-CREB expressed as arbitrary units,were calculated for each cell line after normalization to total ERK1/2, p38 and CREB respectively

     

     

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

  • Effect of dasatinib on endothelial cell actin fiber organization. Subconfluent human microvascular endothelial cells‐1 were treated with dimethyl sulfoxide (A) or dasatinib (B), fixed, permeabilized and stained with phalloıdin (green) for F‐actin or FAK (red) for adhesion plaques. Images were taken in a confocal microscope (1000X).

    Cancer Med, 2017, 6(4):809-818. Dasatinib purchased from Selleck.

    Inhibition of cell growth upon culturing of primary bone marrow cells from an EMS patient and a healthy control in presence of TKIs in vitro. EMS cells showed reduced cell growth compared to the healthy control cells when cultured with ponatinib, dovitinb or dasatinib. Cell growth was evaluated after 72 hours in culture. All samples were normalized to DMSO controls. Non-linear regression curves were fitted for evaluation of IC50 values. Error bars represent mean values and standard deviation of the analyzed replicates.

    Eur J Haematol, 2017, 99(5):442-448. Dasatinib purchased from Selleck.

  • Cell vability test result. Different cell lines (A2C12, Beta D5, Gamma A3, Gamma D12, A549, CaCo2,Hep G2) were treated with different concentration of Dasatinib.

     

     

    Dr. Thomas Kruwel of Fraunhofer-Institute for Toxicology and Experimental Medicine-Dasatinib (BMS-354825) purchased from Selleck. Dasatinib purchased from Selleck.

Purity & Quality Control

Choose Selective Src Inhibitors

Biological Activity

Description Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.
Targets
Abl [1]
(Cell-free assay)
Src [1]
(Cell-free assay)
c-Kit (D816V) [2]
(Cell-free assay)
c-Kit (wt) [2]
(Cell-free assay)
0.6 nM 0.8 nM 37 nM 79 nM
In vitro

Dasatinib is more effective than imatinib in inhibiting the proliferation of Ba/F3 cells expressing wild-type Bcr-Abl and Bcr-Abl mutants, with the exception of T315I. Dasatinib has a two-log (∼325-fold) increased potency relative to imatinib. Dasatinib potently inhibits wild-type Abl kinase and all mutants except T315I over a narrow range. Dasatinib directly targets wild-type and mutant Abl kinase domains and inhibits autophosphorylation and substrate phosphorylation in a concentration-dependent manner. Dasatinib displays 325-fold greater potency compared with imatinib against cells expressing wild-type Bcr-Abl. [1] The percent of colonies of TgE bone marrow cells are decreased from 100% in untreated wells to 4.12% in Dasatinib treated wells. In the presence of Dasatinib, the difference in the percentage of colonies formed by WT and TgE bone marrow cells is statistically significant. Expression of LMP2A is able to promote B lymphocyte survival and proliferation, which can be inhibited by targeting Lyn and/or c-Abl kinases through Dasatinib. [3] Dasatinib treatment inhibits Src signaling, decreases growth, and induces cell cycle arrest and apoptosis in a subset of thyroid cancer cells. Treatment with increasing doses of Dasatinib (0.019 μM to 1.25 μM) for 3 days inhibits the growth of the C643, TPC1, BCPAP, and SW1736 cell lines by about 50% at low nanomolar concentrations, while higher concentrations are required to inhibit the growth of the K1 cell line. Treatment with 10 nM or 50 nM Dasatinib results in a 9-22% increase of cells in the G1 population among BCPAP and SW1736 and K1 cells, and a corresponding 7-18% decrease in the percentage of cells in the S phase. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
M07ep210 MlHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLMO|IhcA>? NVPxWGJZTE2VTx?= NHfXOopKSzVyPUCuNFAxODdizszN NWXReGhUOTd7NU[wPFA>
K562 NIjOWXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPHO|IhcA>? MXnEUXNQ M165[WlEPTB;MD6wNFEh|ryP MWOxO|k2PjB6MB?=
M07e NV3k[VdtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXO3NkBp MYTEUXNQ NGTwbm1KSzVyPUCuNFAyOiEQvF2= M{K5elE4QTV4MEiw
ALL3 M3Sxe2N6fG:2b4jpZ{BCe3OjeR?= NFy1dWYxNjIQvF2= MmXqO|IhcA>? M2nFW2ROW09? MlLJTWM2OD1yLkCwNFQh|ryP NH3q[GEyQTh6OUW0NC=>
CML M3vtRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDvW|YzOCCvaX6= NV\nUFlFTE2VTx?= MYHJR|UxRTBwMECxJO69VQ>? M4XJbFE6OjF7MEG2
BA/F3 NF3rRW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrYUGlHPzJiaB?= MXXEUXNQ M{XKPWlEPTB;Nj61PFkh|ryP NWnIUnI1OjNyOEi2OFQ>
BA/F3 MoHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUC3NkBp M3;zWGROW09? MkC1TY5lfWOnczDhcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDL1[zJINmdGy|IHX4dJJme3OrbnegRoNzNUGkbDDNN|UyXCCvdYThcpQhf2m2aDDJR|UxKG:oIECuNFAxQDQQvF2= M{\W[VI{ODh6NkS0
BA/F3 NF\a[4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorTO|IhcA>? MWnEUXNQ NWflSnEyUW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4Ppcochf2muZDD0fZBmKEKlcj3BZowhf2m2aDDJR|UxKG:oIECuNFA1Pc7:TR?= M4PUNVI{ODh6NkS0
BA/F3 MmXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrJO3k4OiCq MUnEUXNQ NWD3cmlLUW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSmO{LVHicEBVOzF3STDteZRidnRid3n0bEBKSzVyIH;mJFEvPzF2zszN M3XhZ|I{ODh6NkS0
BA/F3 MmPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2G3S|czKGh? NWK2XWJ7TE2VTx?= NETNPYNKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCINEi2V{BufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIECuNFAxQc7:TR?= M3XvZ|I{OzBzN{Cz
BA/F3 MoDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;hO|IhcA>? M4frNWROW09? M2rGXmlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKEV{NUXLJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFMz|ryP M3jXNlI{OzBzN{Cz
BA/F3 M{n4NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHIVplsPzJiaB?= NW[xWpRvTE2VTx?= MYnJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBIOjVyRTDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMEC1Ne69VQ>? NX[3Z2FbOjN|MEG3NFM>
BA/F3 NHHyU5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jnflczKGh? M{TuWWROW09? MWrJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBSOjV{SDDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMEC4{txO NX35SWtnOjN|MEG3NFM>
BA/F3 NI[4NZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDy[odpPzJiaB?= NFrYXlhFVVOR M{f4dGlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKEV|NUnWJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFE{|ryP MlPtNlM{ODF5MEO=
BA/F3 NGHobIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvpO|IhcA>? NV7zeZRjTE2VTx?= MV3JcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4Ppcochf2muZDD0fZBmKEKFUj3BRmwh[XO|ZYPz[YQh[XNiZ4Lve5RpKEmwaHnibZRqd25id3n0bEBKSzVyIH;mJFAvODBzOd88US=> NWO4W4RWOjN|MEG3NFM>
BA/F3 M{D4TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzmdlBkPzJiaB?= M{KzPGROW09? MXnJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEB[OjV|SDDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECyN:69VQ>? NIHMOnMzOzNyMUewNy=>
BA/F3 Mk\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULOTGhIPzJiaB?= NXTNO3g5TE2VTx?= M3qzUGlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKFR|MUXJJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMz62{txO MXSyN|MxOTdyMx?=
BA/F3 NYWzPYFpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13wOlczKGh? NFfvUGlFVVOR NHTtXm9KdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGG|c3Xzd4VlKGG|IHfyc5d1cCCLbnjpZol1cW:wIIfpeIghUUN3MDDv[kAzNjYQvF2= M2PicVI{OzBzN{Cz
T cell NV\sXlZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYK2OpRRPzJiaB?= MVXEUXNQ NUW0OnFVUW6qaXLpeJMh[W62aTDDSFMuKGGwZDDhcpRqKEOGMkitbY5lfWOnZDDUJINmdGxicILvcIln\XKjdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFPPxE1? MVuxO|E2PDVzMh?=
WiDr MkDsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHlZWJuPzJiaB?= MWfEUXNQ MXjJR|UxRTBwMEWyJO69VQ>? Mlf1NVU3OTV3MUK=
PC3 M1;QbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDXO|IhcA>? M4DGN2ROW09? MXfJR|UxRTBwMEC5OEDPxE1? NH;6bZIyPTZzNUWxNi=>
MDA-MB-231 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLqO|IhcA>? MXfEUXNQ MlW4TWM2OD1yLkCxNkDPxE1? NEL0OHMyPTZzNUWxNi=>
Hs578T M{TJdmN6fG:2b4jpZ{BCe3OjeR?= M3\SPFczKGh? MUXEUXNQ MYLHTVUxRTBwMEOg{txO NGnhbIkzPDBzNUOyOy=>
HMEC MV;DfZRwfG:6aXOgRZN{[Xl? NVm5e2NtPzJiaB?= MmXCSG1UVw>? NFzHVGdIUTVyPUGuPEDPxE1? NEHCV3YzPDBzNUOyOy=>
DU145 NWjUfGNoS3m2b4TvfIlkKEG|c3H5 NV3Rd3ZYPzJiaB?= M4jKVmROW09? M1rHdmdKPTB;MD6xOkDPxE1? MVeyOFAyPTN{Nx?=
U251 MUHDfZRwfG:6aXOgRZN{[Xl? Ml\DO|IhcA>? M{PwT2ROW09? NEfWRVhIUTVyPUKuPFEh|ryP MWCyOFAyPTN{Nx?=
NCI60 NGPFboNEgXSxdH;4bYMhSXO|YYm= MWG3NkBp NHzicVBFVVOR Mn3LS2k2OD13Lkeg{txO MkXSNlQxOTV|Mke=
MALME-3M M2WxSGN6fG:2b4jpZ{BCe3OjeR?= Mnz0O|IhcA>? MkXUSG1UVw>? NWDJTItsT0l3ME22MlYyKM7:TR?= MonzNlQxOTV|Mke=
KM12 M36wW2N6fG:2b4jpZ{BCe3OjeR?= NYjUW5FrPzJiaB?= MYLEUXNQ MX7HTVUxRTdwNESg{txO MUKyOFAyPTN{Nx?=
SW620 NFuxR5hEgXSxdH;4bYMhSXO|YYm= NGm3dVI4OiCq NWG2b4ZWTE2VTx?= MkXVS2k2OD16LkSzJO69VQ>? M3\zXlI1ODF3M{K3
RXF 393NL MorkR5l1d3SxeHnjJGF{e2G7 M37FW|Qh\GG7cx?= M{XqTGROW09? MXTJR|UxRTBwMEKxO{DPxE1? MYWyN|I2OzB5NB?=
LXFA 983L M4LLbWN6fG:2b4jpZ{BCe3OjeR?= M2X1dFQh\GG7cx?= NWPHb5RQTE2VTx?= NWSxeG94UUN3ME2wMlA2PjVizszN NWPyfmFWOjN{NUOwO|Q>
PRXF DU145 M1uwZWN6fG:2b4jpZ{BCe3OjeR?= MlraOEBl[Xm| NWfEe5F5TE2VTx?= MlHrTWM2OD1yLkC2NlMh|ryP NUXFeWlXOjN{NUOwO|Q>
PAXF 1657L MWLDfZRwfG:6aXOgRZN{[Xl? M1\FV|Qh\GG7cx?= NXLPUZBETE2VTx?= M{XnT2lEPTB;MD6xNlEh|ryP M{HwclI{OjV|MEe0
CXF 1103L M{PoXmN6fG:2b4jpZ{BCe3OjeR?= MmjPOEBl[Xm| Moq0SG1UVw>? NW\0O2Z2UUN3ME20MlM3KM7:TR?= NYnSUFU{OjN{NUOwO|Q>
GXF251L M4myXWN6fG:2b4jpZ{BCe3OjeR?= NInq[HM1KGSjeYO= NGTBRlRFVVOR NXzGeI5vUUN3ME2yMlI2KM7:TR?= MWGyN|I2OzB5NB?=
NCI-H23 NWnYcllpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFP2NXU4OiCq MYLEUXNQ NX\XVJVrUUN3ME2yMlI4KM7:TR?= NIm1NG8zOzV{MUCyNC=>
HCT116 NUHJbXIxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXS3NkBp MnX5SG1UVw>? M4rGUWlEPTB;Mj6zJO69VQ>? M3vITVI{PTJzMEKw
MCF7 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVy3NkBp MmPySG1UVw>? NH;C[WpKSzVyPUKuOVch|ryP MnvDNlM2OjFyMkC=
NCI-H460 MnfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDRO2g4OiCq NWjLfpJ4TE2VTx?= MmPkTWM2OD16Lkm5JO69VQ>? MlSyNlM2OjFyMkC=
DLD1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU[3NkBp Mkn3SG1UVw>? NYP4W4syUUN3ME20MlYh|ryP M1PlXFI{PTZ5OU[w
NCI-H661 NHLNZVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXoeY5oPzJiaB?= NU\nUYFiTE2VTx?= NWKzbXY4UUN3ME23Mlgh|ryP NUnFc2ljOjN3Nke5OlA>
A549 M2noN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVu1S4YzPzJiaB?= MXLEUXNQ NWO5e3l5UUN3ME24MlIh|ryP NYfJZ2dUOjN3Nke5OlA>
U937 MofNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfifGQ4OiCq MUPEUXNQ MUnJR|UxRTF{LkKg{txO Ml3xNlM2Pjd7NkC=
HEK293 NW\FZYJSTnWwY4Tpc44hSXO|YYm= M2niUFExyqEQvF2= MmjBSG1UVw>? NE\uXlJKdmS3Y3XzJIJqdmSrbnegZYZncW6rdImgeI8hcHWvYX6g[pVtdC2uZX7neIghUGm|LYTh[4dm\CCPeYSxJItqdmG|ZTDlfJBz\XO|ZXSgbY4hUEWNMkmzJINmdGy|IIfpeIghUUN3MDDv[kAxNjB4M988US=> MkK0NlI4PzB4MUC=
HUVEC MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PG[|AvOTYEoN88US=> M13PXFczKGh? MXTEUXNQ M1PwXGlv\HWlZYOgZY51cWGwZ3nv[4VvcWNiYXP0bZZqfHliaX6gTHVXTUNiY3:tZ5VtfHW{ZXSge4l1cCC4YYPjeYxieiC|bX;veIghdXW|Y3zlJINmdGy|IHHzd4V{e2WmIHHzJGlvcGmkaYTpc44hd2ZiY3XscEBoem:5dHigZZQhOC5zNTD1US=> NXTiWpVzOjJ6NUO5PVM>
HUVEC MknCSpVv[3Srb36gRZN{[Xl? M{fGflE2yqEQvF2= MmiyO|IhcA>? NIfZSIJFVVOR M4jaUmlv\HWlZYOgZY51cWGwZ3nv[4VvcWNiYXP0bZZqfHliaX6gTHVXTUNiY3:tZ5VtfHW{ZXSge4l1cCC4YYPjeYxieiC|bX;veIghdXW|Y3zlJINmdGy|IHHzd4V{e2WmIHHzJGlvcGmkaYTpc44hd2ZibnX0e49zcyCob4LtZZRqd25iYYSgNU45KHSxIEG1JJVO MnPLNlI5PTN7OUO=
Plasmodium falciparum MXXGeY5kfGmxbjDBd5NigQ>? MVWxNOKh|ryP NH3OcnEyPSCvaX6= MYrEUXNQ MYPJcohq[mm2czDQcIF{dW:maYXtJIZidGOrcHHyeY0heHKxbHnm[ZJifGmxbjDifUBqdmirYnn0bY5oKHSqZTDGeY5kfGmxbjDv[kBR\kOGUFuxJJBzd3SnaX6ge4l1cCCLQ{WwJI9nKDFwMUhOwG0> Ml3aNlQ2PTB|M{C=
PC3 MkDnSpVv[3Srb36gRZN{[Xl? M3;oNVAvOSEQvF2= M4n0O|UhcA>? MYLEUXNQ NUixSmJsUW6qaXLpeJMhcHWvYX6gVGM{KGOnbHygZYRp\XOrb36gZZQhOTByIH7N M37HNlE6PDZ{OUe1
DU145 NX;NdlNLTnWwY4Tpc44hSXO|YYm= M{X2XFAvOSEQvF2= NYL3c5JnPSCq MnLQSG1UVw>? MmXzTY5pcWKrdIOgbJVu[W5iRGWxOFUh[2WubDDh[Ihme2mxbjDheEAyODBibl2= M1K1PFE6PDZ{OUe1
PC3 NYDp[nZ7U2mwYYPlJGF{e2G7 MUSwMlEh|ryP M3TRbVUhcA>? M3LYUGROW09? NIf0bVdKdmirYnn0d{BkW3KlIHnuJIh2dWGwIGDDN{Bk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hd2ZicHjvd5Bpd3K7bHH0[YQhW3KlIGm0NVYhdGW4ZXygZZQhOTByIH7N NEP0UVQyQTR4Mkm3OS=>
DU145 MVLLbY5ie2ViQYPzZZk> NHuwR2sxNjFizszN MmPmOUBp MXjEUXNQ M{DPOmlvcGmkaYTzJINUemNiaX6gbJVu[W5iRGWxOFUh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKG:oIIDoc5NxcG:{eXzheIVlKFO{YzDZOFE3KGyndnXsJIF1KDFyMDDuUS=> M3W3[|E6PDZ{OUe1
PC3 MYPLbY5ie2ViQYPzZZk> MYOwMlEh|ryP M1jwSFUhcA>? NEniSFRFVVOR M1LuNmlvcGmkaYTzJINUemNiaX6gbJVu[W5iUFOzJINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBw\iCyaH;zdIhwenmuYYTl[EBHSUtiWUW3Ok9[PTd5IHzleoVtKGG2IEGwNEBvVQ>? MnHPNVk1PjJ7N{W=
DU145 M2PMO2tqdmG|ZTDBd5NigQ>? M2K1VFAvOSEQvF2= NFXYU3c2KGh? NUnvXYhXTE2VTx?= M1vxd2lvcGmkaYTzJINUemNiaX6gbJVu[W5iRGWxOFUh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKG:oIIDoc5NxcG:{eXzheIVlKE[DSzDZOVc3N1l3N{egcIV3\WxiYYSgNVAxKG6P NWPBPWdFOTl2NkK5O|U>
Huh7 NHj4cG1CdnSrdnnyZYwhSXO|YYm= MljlNk42KM7:TR?= NVjiUlM3PCCmYYnz NEi1[FZFVVOR MVTJcohq[mm2czD2bZJidCC|cILlZYQhcW5iRHXu[5VmKH[rcoXzMYlv\mWldHXkJIh2dWGwIFj1bFch[2WubIOgZZN{\XO|ZXSgZZMh[WOldX31cIF1cW:wIH;mJJZqemGuIHXueoVtd3CnIIDyc5RmcW5id3n0bIlvKHCncnnueYNt\WG{IILl[4lwdiCjdDCyMlUhfU1? M3m5blE4OzZyNke2
C6/36 NEjWeW5CdnSrdnnyZYwhSXO|YYm= MmTNNk42KM7:TR?= NYDVbVZxPCCmYYnz M3fKSWROW09? MX\Jcohq[mm2czD2bZJidCC|cILlZYQhcW5iRHXu[5VmKH[rcoXzMYlv\mWldHXkJIF{cWGwIITp[4VzKG2xc4H1bZRwKEN4L{O2JINmdGy|IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCxZjD2bZJidCCnbo\lcI9x\SCycn;0[YlvKHerdHjpckBx\XKrboXjcIVieiC{ZXfpc44h[XRiMj61JJVO M2XBbVE4OzZyNke2
U937 MVfGeY5kfGmxbjDBd5NigQ>? M2rjcFEh|ryP MV[xJIg> NIK1fWVFVVOR NFewZ3RT\WS3Y3XzJIJie2GuIGTOSoFteGijIILlcIVie2ViaX6gbJVu[W5iVUmzO{Bk\Wyucx?= M1OyeVE4Pjh2MEm5
U937 MkXRSpVv[3Srb36gRZN{[Xl? NFXLR3MyKM7:TR?= MV:xJIg> MVfEUXNQ NIXjbYRT\WS3Y3XzJGxRWy2rbnT1Z4VlKFSQRnHsdIhiKHKnbHXhd4UhcW5iaIXtZY4hXTl|NzDj[Yxtew>? MUWxO|Y5PDB7OR?=
murine mast cell NEfsRpNHfW6ldHnvckBCe3OjeR?= M2rERVEh|ryP MoHSNlQhcA>? MWjEUXNQ MVPJcohq[mm2czDhcpRq\2WwLXnu[JVk\WRiSVy2JJNm[3KndHnvckBqdiCLZ1WgdJJqdWWmIH3veZNmKG2jc4SgZ4VtdHNiYYSgNUB2VQ>? MW[xO|Y5PDB7OR?=
BV-173 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vkZmlEPTB;MD6wNFAxODBzMEmg{txO NYj0dVhXW0GQR1XS
K-562 NX;5R5BYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHiWYJKSzVyPUCuNFAxODByMk[2JO69VQ>? M2fOcnNCVkeHUh?=
BL-70 NIDCT3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnWTWtEUUN3ME2wMlAxODByMEiyNkDPxE1? NFS2blZUSU6JRWK=
EM-2 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfYTWM2OD1yLkCwNFAxOTB6IN88US=> Mo\uV2FPT0WU
LAMA-84 Ml7JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUj6d2JuUUN3ME2wMlAxODByM{KxJO69VQ>? MW\TRW5ITVJ?
MEG-01 NHTLdpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWraR5hvUUN3ME2wMlAxODByOUig{txO Mo[5V2FPT0WU
EoL-1-cell NX;XOmdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrZSFBYUUN3ME2wMlAxODBzM{Gg{txO Mm\wV2FPT0WU
CTV-1 NWD1[YRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfnPFhKSzVyPUCuNFAxODRyNDFOwG0> Mnj2V2FPT0WU
TE-15 NEG1VlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zK[WlEPTB;MD6wNFU5QSEQvF2= NYPzZmxmW0GQR1XS
NOS-1 NV2ybZpXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTBwMEC2NVMh|ryP M2DkR3NCVkeHUh?=
D-336MG NV3Mc5VET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mor6TWM2OD1yLkCwOlMh|ryP MUHTRW5ITVJ?
LB1047-RCC NIHCOWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DPSGlEPTB;MD6wNFk5QSEQvF2= MXHTRW5ITVJ?
LB996-RCC MnzIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPOUHpQUUN3ME2wMlAxQTlzIN88US=> M{nOW3NCVkeHUh?=
SW982 NIL3e3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfzeWpKSzVyPUCuNFEyOTVizszN NHW0[mVUSU6JRWK=
TK10 NYfFb2tzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHGRopKSzVyPUCuNFEyPzRizszN NFn5UmVUSU6JRWK=
A704 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTXcI9KSzVyPUCuNFE1QTFizszN NFn1To1USU6JRWK=
TE-8 NWPyc3RpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\qVGlEPTB;MD6wNVU4PiEQvF2= MUHTRW5ITVJ?
DOHH-2 M{exfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7q[XExUUN3ME2wMlAyPzF7IN88US=> MV\TRW5ITVJ?
HOP-62 NWXIco85T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTBwMEG4N|Qh|ryP NYXGZoRiW0GQR1XS
TE-12 M1PsbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XodGlEPTB;MD6wNVg3OSEQvF2= NUTuZZlxW0GQR1XS
KGN M4r1eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXHTWM2OD1yLkCxPVQzKM7:TR?= M1PleXNCVkeHUh?=
NCI-H1648 NIjtPWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfGTpZKSzVyPUCuNFIxOTFizszN Ml7IV2FPT0WU
OS-RC-2 M2jUeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fQb2lEPTB;MD6wNlA{KM7:TR?= MoPDV2FPT0WU
GB-1 NXe0SmlGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTBwMEKxOVch|ryP NVfaUY4{W0GQR1XS
RXF393 M4T6dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHZepNKSzVyPUCuNFI{PTdizszN NEjhU41USU6JRWK=
LC-2-ad M2jWWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rQSWlEPTB;MD6wNlU5PiEQvF2= M37xSnNCVkeHUh?=
KS-1 NFfNdmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTBwMEK3N{DPxE1? MUnTRW5ITVJ?
ETK-1 M3i5U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLWTWM2OD1yLkCyPFMzKM7:TR?= MmraV2FPT0WU
SW954 Ml7mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzUSndKSzVyPUCuNFI6OjdizszN MUTTRW5ITVJ?
Becker M1rYNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULkW3l5UUN3ME2wMlA{ODB|IN88US=> MVPTRW5ITVJ?
MZ1-PC NEHrcotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LrN2lEPTB;MD6wN|EyQSEQvF2= NFf6bXRUSU6JRWK=
ES6 M1z5Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTBwMEOxPVMh|ryP NHnOdldUSU6JRWK=
KURAMOCHI MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjnXVhKSzVyPUCuNFM1QDdizszN MYnTRW5ITVJ?
CGTH-W-1 MmPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTBwMEO1OFgh|ryP MUPTRW5ITVJ?
VA-ES-BJ M3fQRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XvbmlEPTB;MD6wN|kxOiEQvF2= Mkj0V2FPT0WU
LXF-289 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DoPWlEPTB;MD6wN|k2PiEQvF2= NW\GSFVrW0GQR1XS
MPP-89 NIjMNIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{WzUGlEPTB;MD6wOFA1QSEQvF2= M{\4OHNCVkeHUh?=
SW872 MmnVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTBwMESxOlEh|ryP NYj2[lJ5W0GQR1XS
SNB75 M4rxemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGC3OYpKSzVyPUCuNFQ1OzVizszN M3zTcHNCVkeHUh?=
PSN1 MnO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\RWmlEPTB;MD6wOFQ4PCEQvF2= NV3OfIJLW0GQR1XS
LB831-BLC MnntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrNOWZKSzVyPUCuNFQ3ODlizszN NXrl[G9YW0GQR1XS
MFH-ino NWLmTpZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DVdGlEPTB;MD6wOFczPCEQvF2= NF3TSFBUSU6JRWK=
TGBC24TKB Mnj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LlemlEPTB;MD6wOFc3OSEQvF2= M2\N[XNCVkeHUh?=
A388 NES4eIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHIbZFKSzVyPUCuNFUxQTVizszN NEPhTW1USU6JRWK=
BB30-HNC M{jKUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTBwMEW0N|ch|ryP MnnoV2FPT0WU
GI-ME-N MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXZRmFwUUN3ME2wMlA3OTF6IN88US=> Mm\vV2FPT0WU
TGBC1TKB M{jI[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\hb4xKSzVyPUCuNFYyPjRizszN M4ftWnNCVkeHUh?=
TE-10 M1rxRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\GTWM2OD1yLkC2N|U4KM7:TR?= NUi1fFJCW0GQR1XS
A498 MkLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPldHlwUUN3ME2wMlA4Ojh2IN88US=> MnG2V2FPT0WU
TE-11 NVnwRoZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDQdmg1UUN3ME2wMlA4QDV6IN88US=> MULTRW5ITVJ?
BB65-RCC Mke2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELkZXBKSzVyPUCuNFgzOjdizszN MXfTRW5ITVJ?
C2BBe1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjuTWM2OD1yLkC4N|A5KM7:TR?= Mn;XV2FPT0WU
NCI-H747 MlHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1y4TWlEPTB;MD6wPFM3OiEQvF2= NIDh[mtUSU6JRWK=
IST-MES1 NV3FbmRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXziVIUyUUN3ME2wMlA5PTV{IN88US=> M1uwSnNCVkeHUh?=
KALS-1 MkLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTBwMEm0PUDPxE1? NYPjZplkW0GQR1XS
GCIY M2H5U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTBwMEm2OVYh|ryP M3zldnNCVkeHUh?=
RL95-2 NHfLfpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlX3TWM2OD1yLkGwN|gh|ryP MlfRV2FPT0WU
TE-1 NGLj[W5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPBTWM2OD1yLkGwOVQh|ryP NUfl[lVtW0GQR1XS
NCI-H1355 NU\WcXlYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjSbYhKSzVyPUCuNVExOjhizszN MmfSV2FPT0WU
SW962 NW\yRZZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPj[5NPUUN3ME2wMlEyOjl{IN88US=> MmfCV2FPT0WU
KLE MmnOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVj4N2hXUUN3ME2wMlEyOzF5IN88US=> NVv2WoFEW0GQR1XS
MC116 NXnu[FVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4n0V2lEPTB;MD6xNVQyKM7:TR?= NFnTSZNUSU6JRWK=
NMC-G1 M3\zSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TLZWlEPTB;MD6xNVYxPiEQvF2= MlS4V2FPT0WU
KU812 NHnXVYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGf2NFRKSzVyPUCuNVE5QDNizszN MXfTRW5ITVJ?
COLO-829 NIja[2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPvfHB6UUN3ME2wMlEzOjF|IN88US=> NHH3XVFUSU6JRWK=
NTERA-S-cl-D1 NWmxNJNkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTBwMUKyPFMh|ryP M{XCOHNCVkeHUh?=
IST-MEL1 M1XHTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTBwMUO0OUDPxE1? M{GyUXNCVkeHUh?=
MLMA MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vrSmlEPTB;MD6xOFA{OiEQvF2= NXHweZRGW0GQR1XS
LS-123 M3jUOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;sTWM2OD1yLkG0NFY1KM7:TR?= MoPMV2FPT0WU
LB2518-MEL MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4[1bGlEPTB;MD6xOFE3OiEQvF2= M1;qPXNCVkeHUh?=
NB69 M2LveGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTBwMUS0N|Yh|ryP MVrTRW5ITVJ?
8-MG-BA Mmf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfleFJIUUN3ME2wMlE2PDV6IN88US=> NHu5SVdUSU6JRWK=
K5 MnHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofLTWM2OD1yLkG2OFg6KM7:TR?= NWLIbGVEW0GQR1XS
KINGS-1 NXnLVJV[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPnTItIUUN3ME2wMlE3PjZ4IN88US=> MV7TRW5ITVJ?
SF268 Mof4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2L5SGlEPTB;MD6xO|QxPCEQvF2= NXfycGxDW0GQR1XS
PF-382 M3TJ[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILGOFlKSzVyPUCuNVc3PzhizszN NHTxbIlUSU6JRWK=
SH-4 M1nweGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYL4e5NQUUN3ME2wMlE5PDF|IN88US=> NYjPbm97W0GQR1XS
NALM-6 NIjIdohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TEV2lEPTB;MD6xPVI6PSEQvF2= Ml3yV2FPT0WU
CP66-MEL MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTBwMUm1N|Eh|ryP NEPs[WNUSU6JRWK=
697 MmTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTBwMUm5PFch|ryP NY\tUYhYW0GQR1XS
CP67-MEL Mnq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPTdVduUUN3ME2wMlIxPDh6IN88US=> NFPnVY9USU6JRWK=
DSH1 MlH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PiO2lEPTB;MD6yOFAxOSEQvF2= NXK5fFcxW0GQR1XS
HCE-4 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvPNJZKSzVyPUCuNlY1OzlizszN NEfnSW1USU6JRWK=
MZ2-MEL MnOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Drd2lEPTB;MD6yPFU{PyEQvF2= NVn6XJdTW0GQR1XS
BL-41 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTBwMkmxNlMh|ryP MV;TRW5ITVJ?
HUTU-80 NWfSZ4JtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjre2RpUUN3ME2wMlMyPDJizszN M1nNTXNCVkeHUh?=
LOXIMVI Mk\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXPTWM2OD1yLkOxOVA{KM7:TR?= M4ixenNCVkeHUh?=
no-10 NYDtdXYyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIj1emFKSzVyPUCuN|E6OzFizszN Mor5V2FPT0WU
KARPAS-422 NEf3XFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHsSHhlUUN3ME2wMlM{QTl5IN88US=> NWjmdlJOW0GQR1XS
SW684 M{HFOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPQTWM2OD1yLkO0PVgh|ryP NGj1bW1USU6JRWK=
SF126 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17HUGlEPTB;MD6zOVQyKM7:TR?= NGi5NFFUSU6JRWK=
D-263MG NGj0Z21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLJW3FEUUN3ME2wMlM3OjJ2IN88US=> NFnMS4ZUSU6JRWK=
OVCAR-4 NHfMeVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnW[Yh4UUN3ME2wMlM4PDN|IN88US=> MVPTRW5ITVJ?
BB49-HNC MlG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTBwM{i1PVkh|ryP Ml3yV2FPT0WU
ONS-76 MnfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PZSmlEPTB;MD60Nlk2OSEQvF2= MofPV2FPT0WU
MZ7-mel NFHiV49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4[4VGlEPTB;MD60O|kyOSEQvF2= MlzvV2FPT0WU
RCC10RGB M{H6[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzSTWM2OD1yLkS5NVEh|ryP NVnEZnQyW0GQR1XS
BOKU NHyz[IhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\HfJY3UUN3ME2wMlQ6OTN|IN88US=> Ml7OV2FPT0WU
no-11 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDUO5BKSzVyPUCuOVAzOjhizszN MknMV2FPT0WU
IST-SL2 NFPQUYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDr[Jo3UUN3ME2wMlUxOzB{IN88US=> NX3WO3BPW0GQR1XS
RKO NVXWdG1RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnPTWM2OD1yLkWyPVY3KM7:TR?= NULMU4p7W0GQR1XS
HT-144 NYXldYU2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;Db41rUUN3ME2wMlU{PjB7IN88US=> NULnXIExW0GQR1XS
NCI-H446 M3jmXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTBwNkK3OkDPxE1? MX\TRW5ITVJ?
QIMR-WIL NE\aR|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NET6WWVKSzVyPUCuO|A3OjlizszN MWjTRW5ITVJ?
MHH-PREB-1 M3vxTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfhTWM2OD1yLke0OFY6KM7:TR?= MVTTRW5ITVJ?
EW-16 NH[0R5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3ZTWM2OD1yLke2NVc5KM7:TR?= MUDTRW5ITVJ?
EW-24 NUHxemZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnoZnNKSzVyPUCuO|gyPjVizszN NFHaPWFUSU6JRWK=
LB373-MEL-D MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTBwOEK1NFgh|ryP NYfuU2xXW0GQR1XS
TE-9 Mmj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlqxTWM2OD1yLki3OVMzKM7:TR?= M1fIUHNCVkeHUh?=
A3-KAW M4q3OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nBU2lEPTB;MD65PFQ2OiEQvF2= MmXnV2FPT0WU
A101D NGXobGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzwUmlKSzVyPUGuNFMxPDNizszN MkK4V2FPT0WU
OCUB-M NFKwV2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIG0fplKSzVyPUGuNFQ1OTJizszN NH7FdHlUSU6JRWK=
ES4 M1jibGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlG3TWM2OD1zLkC1NVQ2KM7:TR?= MX\TRW5ITVJ?
TE-6 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTFwMkGyNlYh|ryP NETSc5FUSU6JRWK=
D-502MG M2PyWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3LTWM2OD1zLkKzN|c3KM7:TR?= NY\ke5BxW0GQR1XS
KNS-42 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTFwMkS0NVIh|ryP MmXNV2FPT0WU
SNU-C2B MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTFwM{C1PFkh|ryP M2TQUHNCVkeHUh?=
NCI-H1838 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnUTWM2OD1zLkOwO|M{KM7:TR?= M2e0b3NCVkeHUh?=
NKM-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHTTmFKSzVyPUGuN|A5PTlizszN NWfHUplbW0GQR1XS
GI-1 MnvoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;EeGlEPTB;MT6zOlIzKM7:TR?= MV3TRW5ITVJ?
NB5 Mm\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;rTWM2OD1zLkO5PFI4KM7:TR?= M3PEcHNCVkeHUh?=
CAS-1 M{fJbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULz[G84UUN3ME2xMlQxQTl{IN88US=> NF;hSXFUSU6JRWK=
HCE-T M1ztU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\uWopKSzVyPUGuOVY4OTRizszN NEm5OG1USU6JRWK=
SBC-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjwTWM2OD1zLkW3PVg1KM7:TR?= NF7PTGpUSU6JRWK=
JiyoyeP-2003 M4jDfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4CxdWlEPTB;MT63N|Q3PiEQvF2= NWXKTGZLW0GQR1XS
TE-5 NW\SPINYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTFwN{mxN|kh|ryP NUf3OIdoW0GQR1XS
CAN Mn7wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTFwOEKyOVIh|ryP MVHTRW5ITVJ?
SK-UT-1 NXHB[nJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vHSGlEPTB;Mj6xOlY6OyEQvF2= NGTxVJpUSU6JRWK=
JVM-2 M2nMXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnaOWpGUUN3ME2yMlM3Ojh2IN88US=> MYXTRW5ITVJ?
LB771-HNC NFvLeoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NICzR|BKSzVyPUKuOVc2PTFizszN MXfTRW5ITVJ?
NCCIT MnXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLWTWM2OD1{Lki2OlE3KM7:TR?= M3fGcXNCVkeHUh?=
NCI-H2126 M4HHb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTJwOEe1OVIh|ryP MmHZV2FPT0WU
Calu-6 NGftUIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFW1cWlKSzVyPUOuNFU4PDFizszN MVjTRW5ITVJ?
SK-LMS-1 M{DSXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zze2lEPTB;Mz6xNVg5PiEQvF2= M4nHcXNCVkeHUh?=
ARH-77 M3y5Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HrUWlEPTB;Mz60OlkyPSEQvF2= NXuzbWNiW0GQR1XS
NB17 NIr0b5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnkTWM2OD1|Lk[zPFQ4KM7:TR?= MnnSV2FPT0WU
A253 MkWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTNwN{OyOFYh|ryP MoS0V2FPT0WU
OPM-2 NX3WZlNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17RNGlEPTB;ND6yO|Y5PSEQvF2= MljWV2FPT0WU
MV-4-11 NGX4dmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXBUGdKSzVyPUSuN|Y1PTRizszN MmjPV2FPT0WU
SR NYm4UIRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;I[FJKSzVyPUSuOFk6PTRizszN MlK0V2FPT0WU
KG-1 M3;NOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fmR2lEPTB;ND62NFg1PSEQvF2= MWXTRW5ITVJ?
OCI-AML2 NIHBVJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU[3bodDUUN3ME21Mlg3OTV2IN88US=> MVHTRW5ITVJ?
D-247MG M334Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYr0TI5KUUN3ME22MlEzPTF7IN88US=> M{fRWnNCVkeHUh?=
DJM-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\kTWM2OD14LkS4OVU5KM7:TR?= NHfKR4JUSU6JRWK=
RPMI-6666 M{PFeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTLTWM2OD15LkK3NFY4KM7:TR?= NWPP[|ZwW0GQR1XS
KARPAS-45 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTdwNUG2O|Eh|ryP NIXpOWRUSU6JRWK=
LP-1 M2DPTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTdwNUS3PFIh|ryP NH;6UYNUSU6JRWK=
RS4-11 M{f1R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEiyT|lKSzVyPUeuOlU4QDdizszN MmHZV2FPT0WU
DU-4475 MmfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXGyW2xjUUN3ME24MlIyPjV{IN88US=> M4n6fnNCVkeHUh?=
MONO-MAC-6 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXe5[Wc2UUN3ME24MlI4ODZ4IN88US=> MYnTRW5ITVJ?
NCI-SNU-16 M4nl[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRThwNU[xNlgh|ryP MULTRW5ITVJ?
SJSA-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXviPZk1UUN3ME24MlczQDB3IN88US=> MXPTRW5ITVJ?
MMAC-SF M1vqSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfVc3hVUUN3ME24Mlc6OzB5IN88US=> NFnISG5USU6JRWK=
SK-NEP-1 MkPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLNTmoxUUN3ME24Mlg6OTV3IN88US=> NGfpc2JUSU6JRWK=
J-RT3-T3-5 NXj1UoJET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrtdXFKSzVyPUiuPVY2OjlizszN M2LoXnNCVkeHUh?=
SKM-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTlwMEG3N|Qh|ryP MoT5V2FPT0WU
LB2241-RCC NI[yRY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vVbGlEPTB;OT6wNlAyOiEQvF2= NFS1[npUSU6JRWK=
SIG-M5 NEDLNWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnQSGZKSzVyPUmuNFI1QTNizszN MXPTRW5ITVJ?
EVSA-T M162[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXn1N45JUUN3ME25MlI4Pzl|IN88US=> MoiwV2FPT0WU
GT3TKB MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTlwM{W1OFYh|ryP MoPPV2FPT0WU
NB6 NYq2dYVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXXTWM2OD17LkmyNlU6KM7:TR?= M4nIU3NCVkeHUh?=
EHEB MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3m5RmlEPTB;MUCuNFY2PiEQvF2= NWmyNWlUW0GQR1XS
HEL NHL0U2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTFyLkS3O|Yh|ryP M3fjTXNCVkeHUh?=
ALL-PO MojyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fk[2lEPTB;MUCuO|k{QCEQvF2= NFnLe25USU6JRWK=
TGW NVXoeVRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nYSmlEPTB;MUGuNlgzQCEQvF2= Mk[zV2FPT0WU
BC-3 NGrJOGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjqXGJKSzVyPUGyMlEyOzhizszN NHvncJVUSU6JRWK=
IA-LM NYT3ZmI3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33iNmlEPTB;MUKuOFQ1PSEQvF2= MonXV2FPT0WU
UACC-257 NGHUUG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHFVlBKSzVyPUGyMlkyQThizszN NFGzWoNUSU6JRWK=
KP-N-YS M1z1emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3L5TWlEPTB;MUKuPVI5OyEQvF2= NYf1N|FIW0GQR1XS
Raji M2H1Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLkTWM2OD1zMz63OFk4KM7:TR?= NF60RlFUSU6JRWK=
SF539 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HZemlEPTB;MUOuPFU2PyEQvF2= MXfTRW5ITVJ?
DMS-153 NF;KOXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTF2LkCwNlgh|ryP M1HKZnNCVkeHUh?=
L-540 M2DKdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPl[FlKSzVyPUG1MlA3PzJizszN MYfTRW5ITVJ?
MN-60 M1jZWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvXTWM2OD1zNT6xPVc6KM7:TR?= M1PIfnNCVkeHUh?=
RPMI-8866 NHG5Z4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PVeGlEPTB;MUeuOFQ2PCEQvF2= NVK4R2VDW0GQR1XS
NCI-H510A NHezPJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnyTWM2OD1zOT6zPVc{KM7:TR?= MY\TRW5ITVJ?
NB13 Mne2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmmzTWM2OD1zOT60PFc4KM7:TR?= M2LQZXNCVkeHUh?=
HAL-01 NWX0R404T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTF7Lke1OFMh|ryP NFjHb4VUSU6JRWK=
NCI-H720 MlLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fOTmlEPTB;MkCuNlc{OyEQvF2= MYHTRW5ITVJ?
REH NUHRcHdTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\YcpVKUUN3ME2yNE43OzV5IN88US=> MmTLV2FPT0WU
KNS-81-FD MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rrcGlEPTB;MkOuNVQ3KM7:TR?= MXvTRW5ITVJ?
HC-1 Ml73S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzLdXhKSzVyPUK0MlU2PTFizszN MWjTRW5ITVJ?
NCI-H2141 NH3PUIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTJ2Lke3OVQh|ryP M2fJbXNCVkeHUh?=
MOLT-4 MlnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\XTWM2OD1{Nj62O|U{KM7:TR?= NVfsWnhXW0GQR1XS
OMC-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTJ5LkG0NlIh|ryP NVXZVoVXW0GQR1XS
LC-1F MljaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILKRYxKSzVyPUK3MlMzPDVizszN NF6zcXBUSU6JRWK=
NCI-H1304 M1\WZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHuw[ZNKSzVyPUK4MlE3OjhizszN M1nwWHNCVkeHUh?=
BC-1 NXHZTVlHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPBZph3UUN3ME2yPE43PTFizszN M4\1fHNCVkeHUh?=
NCI-H64 M4XGNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjsN4xKSzVyPUK5MlYzPTNizszN Mm\pV2FPT0WU
MOLT-16 M4T6WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHw[GVrUUN3ME2yPU43Ojl{IN88US=> M4jldXNCVkeHUh?=
U-87-MG MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHK2OJhKSzVyPUOwMlc3PiEQvF2= NVX5T2J{W0GQR1XS
GAK MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTmTWM2OD1|MT6yOlg3KM7:TR?= MmntV2FPT0WU
ES8 M3vnbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTN{LkGyOVIh|ryP MlLCV2FPT0WU
HCC1599 NHfMenRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHMeYNKSzVyPUOyMlM{OjVizszN M1PT[XNCVkeHUh?=
EB-3 NWeydYZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTN2LkOxNVch|ryP M{XDNnNCVkeHUh?=
HCC1187 M2PoZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzPTWM2OD1|NT64NFUzKM7:TR?= NUXmZ4NMW0GQR1XS
SK-PN-DW NXyxdolvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3npbmlEPTB;M{[uNVk1OyEQvF2= MlXSV2FPT0WU
JVM-3 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\iPHZKSzVyPUO3MlI{OzhizszN NXniWlUyW0GQR1XS
HCC2157 MmXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrSTWM2OD1|Nz65PVQ3KM7:TR?= NYnVRnFRW0GQR1XS
A4-Fuk M3\FW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1:wZWlEPTB;M{iuNVAxQSEQvF2= NYPkXI13W0GQR1XS
COR-L279 NELLUFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1O1PWlEPTB;NECuNlg2OSEQvF2= MkjTV2FPT0WU
DEL MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYj6fopsUUN3ME20NU46ODh4IN88US=> NEfsS5VUSU6JRWK=
NCI-H1395 NIf0OoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13BW2lEPTB;NEKuNFE3OyEQvF2= NHO2N3ZUSU6JRWK=
MHH-NB-11 M{HReGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzxTWM2OD12Mz6wPFE5KM7:TR?= MVjTRW5ITVJ?
NCI-H2107 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXWVGtKSzVyPUSzMlQ5PDZizszN MmjrV2FPT0WU
NEC8 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrzXJZnUUN3ME20OE4{OzZizszN M2jWd3NCVkeHUh?=
COLO-684 NXT0SGJNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzuTWM2OD12Nj6yNlU5KM7:TR?= MknMV2FPT0WU
LS-411N NIfoOI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIH5T2tKSzVyPUS4MlQ4PDhizszN NEjmTVNUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo Dasatinib reverses splenomegaly in LMP2A/MYC double transgenic mice. Dasatinib specifically prevents colony formation by LMP2A expressing bone marrow B cells and decreased spleen size in the TgE mice. Spleen mass is significantly decreased among Dasatinib treated Tg6/λ-MYC mice when compared to the control group. Dasatinib inhibits lymphadenopathy in LMP2A/MYC double transgenic mice. Dasatinib reverses splenomegaly in Rag1KO mice engrafted with tumor cells from LMP2A/MYC double transgenic mice. Dasatinib therapy inhibits Lyn phosphorylation in B lymphocyte tumors expressing LMP2A. [3]

Protocol

Kinase Assay:

[1]

+ Expand

Kinase autophosphorylation assays:

Kinase assays using wild-type and mutant glutathione S-transferase (GST)-Abl fusion proteins (c-Abl amino acids 220-498) are done. GST-Abl fusion proteins are released from glutathione-Sepharose beads before use; the concentration of ATP is 5 μM. Immediately before use in kinase autophosphorylation and in vitro peptide substrate phosphorylation assays, GST-Abl kinase domain fusion proteins are treated with LAR tyrosine phosphatase. After 1-hour incubation at 30 °C, LAR phosphatase is inactivated by addition of sodium vanadate (1 mM). Immunoblot analysis comparing untreated GST-Abl kinase to dephosphorylated GST-Abl kinase is routinely done using phosphotyrosine-specific antibody 4G10 to confirm complete (>95%) dephosphorylation of tyrosine residues and c-Abl antibody CST 2862 to confirm equal loading of GST-Abl kinase. The Dasatinib concentration range is extended to 1,000 nM for mutant T315I. These same inhibitor concentrations are used for the in vitro peptide substrate phosphorylation assays. The three inhibitors are tested over these same concentration ranges against GST-Src kinase and GST-Lyn kinase.
Cell Research:

[1]

+ Expand
  • Cell lines: Ba/F3 cell lines
  • Concentrations: ~32 nM
  • Incubation Time: 72 hours
  • Method:

    Ba/F3 cell lines are seeded in triplicate and incubated with escalating concentrations of Dasatinib for 72 hours. Proliferation is measured using a methanethiosulfonate-based viability assay. IC50 and IC90 values are reported as the mean of three independent experiments done in quadruplicate. The inhibitor concentration ranges are 0 nM to 32 nM (Dasatinib). The Dasatinib concentration range is extended to 200 nM for mutant T315I.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: EμLMP2A (TgE and Tg6 strains), MYC (λ-MYC), and LMP2A/λ-MYC double transgenic mice (Tg6/λ-MYC)
  • Formulation: DMSO
  • Dosages: 30 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 98 mg/mL (200.81 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 488.01
Formula

C22H26ClN7O2S

CAS No. 302962-49-8
Storage powder
in solvent
Synonyms BMS-354825

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03041701 Recruiting Rhabdomyosarcoma|Rhabdomyosarcoma- Alveolar|Rhabdomyosarcoma-Embryonal National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 7 2017 Phase 1|Phase 2
NCT02011945 Active not recruiting Chronic Myeloid Leukemia Bristol-Myers Squibb February 7 2014 Phase 1
NCT02389309 Recruiting Solid Tumors M.D. Anderson Cancer Center October 5 2015 Phase 1
NCT02744768 Recruiting Acute Lymphoblastic Leukemia Gruppo Italiano Malattie EMatologiche dell''Adulto May 31 2017 Phase 2
NCT01999985 Active not recruiting Lung Cancer|Non-small Cell Lung Cancer (NSCLC) H. Lee Moffitt Cancer Center and Research Institute|Boehringer Ingelheim|Bristol-Myers Squibb December 31 2013 Phase 1
NCT01660971 Active not recruiting Metastatic Pancreatic Adenocarcinoma|Recurrent Pancreatic Carcinoma|Stage III Pancreatic Cancer AJCC v6 and v7|Stage IV Pancreatic Cancer AJCC v6 and v7 National Cancer Institute (NCI) July 30 2012 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    what’s the difference between S1021 and S7782? Which one is better for in vivo studies?

  • Answer:

    Usually, hydrate will be more stable and dissolve better than free base. But this compound (S1021) dissolves better in DMSO than hydrate one (S7782).

  • Question 2:

    Can I give dasatinib to mice by oral gavage? If so, how to dissolve the drug?

  • Answer:

    Our S1021 Dasatinib in 1% DMSO+30% PEG 300+1% Tween 80 at 30 mg/ml is a suspension which you can administrate to mice via oral gavage. If you want a clear solution, it can be dissolved in 4% DMSO+30% PEG 300+5% Tween 80+ddH2O at 5 mg/ml clearly.

Src Signaling Pathway Map

Src Inhibitors with Unique Features

Related Src Products

Tags: buy Dasatinib | Dasatinib supplier | purchase Dasatinib | Dasatinib cost | Dasatinib manufacturer | order Dasatinib | Dasatinib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID